Joseph Eder

WORK HISTORY

EDUCATION

ABOUT JOSEPH EDER

I became the principal clinical investigator of the Harvard UO1 Phase I program in 1995, uniting the clinical efforts at the DFCI, BWH, MGH and BIDMC. In 1998, I became the Clinical Director of the Experimental Therapeutics Program for the Dana-Farber/Harvard Cancer Center. As Clinical Director, I assumed overall responsibility for the phase I cancer therapeutic trials performed at the DF/HCC. In 2004 I assumed the responsibilities as the Clinical Director of the DFCI General Cancer Research Center at the Dana-Farber/ Brigham and Women’s Hospital. A NIH U01 grant [UO1CA 62•••13] formed the basic funding mechanism. These clinical and basic research activities involved collaboration with clinical and basic scientists at Harvard and elsewhere, the Cancer Therapy Evaluation Program of the National Cancer Institute, presentations at national and international meetings, and correspondence with a number of leaders in the field of cancer drug development. At AstraZeneca PLC 20••••12, I was appointed to be the Medical Science Director and was the Global Disease Area Clinical Expert for Hematology. In 2012, I had responsibility for 3 agents in clinical trials and 2 in preclinical development. As MSD, I supervised 3 physicians in Asia, 4 in the US, 1 in the UK and have a supervisory role for 28 scientists and professional personnel. I joined the Yale Cancer Center in 2012 as Director of the Early Drug Development Program and Assistant Director of Experimental Therapeutics